By combining various treatment modalities such as targeted therapy, immune checkpoint inhibitors, CAR-T cell therapy, and antibody-based drugs in a rationally personalized manner according to the genetic, protein, and immune microenvironmental characteristics of IP-LBCL patients, the combination of BTK inhibitors with PD-1/PD-L1 inhibitors may synergistically overcome tumor immune escape, enhancing the efficacy and reducing adverse reactions in IP-LBCL patients. This evidence concerns the gene BTK and neoplasm.